-
Something wrong with this record ?
Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis
V. Caisová, O. Uher, P. Nedbalová, I. Jochmanová, K. Kvardová, K. Masáková, G. Krejčová, L. Paďouková, J. Chmelař, J. Kopecký, J. Ženka,
Language English Country Netherlands
Document type Journal Article
- MeSH
- Adenocarcinoma immunology pathology therapy MeSH
- Phagocytosis * MeSH
- Imidazoles therapeutic use MeSH
- Immunotherapy MeSH
- Teichoic Acids therapeutic use MeSH
- Lipopolysaccharides therapeutic use MeSH
- Mannans therapeutic use MeSH
- Melanoma, Experimental immunology pathology therapy MeSH
- Mice, Inbred C57BL MeSH
- Cell Line, Tumor MeSH
- Pancreatic Neoplasms immunology pathology therapy MeSH
- Neutrophils immunology MeSH
- Poly I-C therapeutic use MeSH
- Toll-Like Receptors agonists MeSH
- Tumor Burden drug effects MeSH
- Lymphocytes, Tumor-Infiltrating immunology MeSH
- Animals MeSH
- Check Tag
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Immunotherapy emerges as a fundamental approach in cancer treatment. Up to date, the efficacy of numerous different immunotherapies has been evaluated. The use of microorganisms or their parts for immune cell activation, referred to as Pathogen-Associated Molecular Patterns (PAMPs), represents highly promising concept. The therapeutic effect of PAMPs can be further amplified by suitable combination of different types of PAMPs such as Toll like receptor (TLR) agonists and phagocytosis activating ligands. Previously, we used the combination of phagocytosis activating ligand (mannan) and mixture of TLR agonists (resiquimod (R-848), poly(I:C), inactivated Listeria monocytogenes) for successful treatment of melanoma in murine B16-F10 model. In the present study, we optimized the composition and timing of previously used mixture. Therapeutic mixture based on well-defined chemical compounds consisted of mannan anchoring to tumor cell surface by biocompatible anchor for membranes (BAM) and TLR agonists resiquimod, poly(I:C), and lipoteichoic acid (LTA). The optimization resulted in (1) eradication of advanced stage progressive melanoma in 83% of mice, (2) acquisition of resistance to tumor re-transplantation, and (3) potential anti-metastatic effect. After further investigation of mechanisms, underlying anti-tumor responses, we concluded that both innate and adaptive immunity are activated and involved in these processes. We tested the efficacy of our treatment in Panc02 murine model of aggressive pancreatic tumor as well. Simultaneous application of agonistic anti-CD40 antibody was necessary to achieve effective therapeutic response (80% recovery) in this model. Our results suggest that herein presented immunotherapeutic approach is a promising cancer treatment strategy with the ability to eradicate not only primary tumors but also metastases.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000815
- 003
- CZ-PrNML
- 005
- 20211209143518.0
- 007
- ta
- 008
- 190107s2018 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.intimp.2018.03.038 $2 doi
- 035 __
- $a (PubMed)29635103
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Caisová, Veronika $u Department of Medical Biology, Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic.
- 245 10
- $a Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis / $c V. Caisová, O. Uher, P. Nedbalová, I. Jochmanová, K. Kvardová, K. Masáková, G. Krejčová, L. Paďouková, J. Chmelař, J. Kopecký, J. Ženka,
- 520 9_
- $a Immunotherapy emerges as a fundamental approach in cancer treatment. Up to date, the efficacy of numerous different immunotherapies has been evaluated. The use of microorganisms or their parts for immune cell activation, referred to as Pathogen-Associated Molecular Patterns (PAMPs), represents highly promising concept. The therapeutic effect of PAMPs can be further amplified by suitable combination of different types of PAMPs such as Toll like receptor (TLR) agonists and phagocytosis activating ligands. Previously, we used the combination of phagocytosis activating ligand (mannan) and mixture of TLR agonists (resiquimod (R-848), poly(I:C), inactivated Listeria monocytogenes) for successful treatment of melanoma in murine B16-F10 model. In the present study, we optimized the composition and timing of previously used mixture. Therapeutic mixture based on well-defined chemical compounds consisted of mannan anchoring to tumor cell surface by biocompatible anchor for membranes (BAM) and TLR agonists resiquimod, poly(I:C), and lipoteichoic acid (LTA). The optimization resulted in (1) eradication of advanced stage progressive melanoma in 83% of mice, (2) acquisition of resistance to tumor re-transplantation, and (3) potential anti-metastatic effect. After further investigation of mechanisms, underlying anti-tumor responses, we concluded that both innate and adaptive immunity are activated and involved in these processes. We tested the efficacy of our treatment in Panc02 murine model of aggressive pancreatic tumor as well. Simultaneous application of agonistic anti-CD40 antibody was necessary to achieve effective therapeutic response (80% recovery) in this model. Our results suggest that herein presented immunotherapeutic approach is a promising cancer treatment strategy with the ability to eradicate not only primary tumors but also metastases.
- 650 _2
- $a adenokarcinom $x imunologie $x patologie $x terapie $7 D000230
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a imidazoly $x terapeutické užití $7 D007093
- 650 _2
- $a imunoterapie $7 D007167
- 650 _2
- $a lipopolysacharidy $x terapeutické užití $7 D008070
- 650 _2
- $a tumor infiltrující lymfocyty $x imunologie $7 D016246
- 650 _2
- $a mannany $x terapeutické užití $7 D008351
- 650 _2
- $a melanom experimentální $x imunologie $x patologie $x terapie $7 D008546
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a neutrofily $x imunologie $7 D009504
- 650 _2
- $a nádory slinivky břišní $x imunologie $x patologie $x terapie $7 D010190
- 650 12
- $a fagocytóza $7 D010587
- 650 _2
- $a poly I-C $x terapeutické užití $7 D011070
- 650 _2
- $a kyseliny teichoové $x terapeutické užití $7 D013682
- 650 _2
- $a toll-like receptory $x agonisté $7 D051193
- 650 _2
- $a tumor burden $x účinky léků $7 D047368
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Uher, Ondřej $u Department of Medical Biology, Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic.
- 700 1_
- $a Nedbalová, Pavla $u Department of Medical Biology, Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic.
- 700 1_
- $a Jochmanová, Ivana $u 1st Department of Internal Medicine, Medical Faculty of P. J. Šafárik University in Košice, Košice, Slovakia. $7 xx0267304
- 700 1_
- $a Kvardová, Karolína $u Department of Medical Biology, Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic.
- 700 1_
- $a Masáková, Kamila $u Department of Medical Biology, Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic.
- 700 1_
- $a Krejčová, Gabriela $u Department of Medical Biology, Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic.
- 700 1_
- $a Paďouková, Lucie $u Department of Medical Biology, Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic.
- 700 1_
- $a Chmelař, Jindřich $u Department of Medical Biology, Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic.
- 700 1_
- $a Kopecký, Jan $u Department of Medical Biology, Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, v.v.i., České Budějovice, Czech Republic.
- 700 1_
- $a Ženka, Jan $u Department of Medical Biology, Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic. Electronic address: jzenka@gmail.com.
- 773 0_
- $w MED00006034 $t International immunopharmacology $x 1878-1705 $g Roč. 59, č. - (2018), s. 86-96
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29635103 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20211209143517 $b ABA008
- 999 __
- $a ok $b bmc $g 1364811 $s 1038938
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 59 $c - $d 86-96 $e 20180407 $i 1878-1705 $m International immunopharmacology $n Int Immunopharmacol $x MED00006034
- LZP __
- $a Pubmed-20190107